CyberArk Unveils First-Of-Its-Kind Machine Identity Security Solution To Secure Workloads Across Every Environment
10.4.2025 15:00:00 CEST | Business Wire | Press Release
CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced the availability of CyberArk Secure Workload Access Solution,1 delivering the industry's most comprehensive protection for all non-human identities that matter. The solution will enable security teams to gain visibility and control over the entire machine identity lifecycle, from creation and governance to automated rotation and renewal.
Machine identities proliferate in cloud-native architectures, including applications, workloads, and automated processes. Unlike solutions focusing on singular machine identity types, CyberArk's layered approach will enable organizations to enforce least privilege, mitigate risk, and prevent credential-based attacks for all workloads across hybrid and multi-cloud environments.
In addition, CyberArk has extended its discovery and context capabilities, designed to help security teams take the first steps to modernize workload authentication by assessing, understanding and eliminating risks tied to unprotected machine identities. These automated capabilities help teams generate an inventory of secrets, certificates and information about their environment, understand the risk of compromise tied to each machine identity and prioritize mitigation actions.
"Modern, cloud and ephemeral workloads mean authentication can be fragmented, making access control challenging and resulting in a large, unprotected attack surface that dramatically increases the risk of breaches," said Kurt Sand, GM of Machine Identity Security at CyberArk. "Recent high-profile attacks have highlighted the urgent need for a modern, identity-first model that enforces universal and unique workload identities to help organizations confidently secure workloads across their entire hybrid and multi-cloud estate."
The core of the Secure Workload Access Solution is CyberArk Workload Identity Manager. This lightweight, distributed, and cloud-native machine identity issuer goes beyond traditional Public Key Infrastructure (PKI) systems that cannot scale to the needs of ephemeral cloud workloads. The new solution will integrate Workload Identity Manager with CyberArk Secrets Manager, enabling secure access for all workloads as cloud-native and containerized environments grow.
The CyberArk Secure Workload Access Solution will allow workloads running in virtualized environments to be automatically identified for access to cloud services and cloud provider environments, securing dynamic, cloud-native workloads like Kubernetes and service mesh. It will provide the capability to:
- Securely connect on-premises and cloud workloads across environments with unique and universal SPIFFE2 identities that work with existing identities, applications, clouds and SaaS services.
- Integrate seamlessly with secrets management for existing API key and access token authentication, as well as other secrets.
- Discover and assess risk across all workloads, making it easier to detect threats, enforce security policies and prevent unauthorized access.
Further information:
- Learn more about the CyberArk Secure Workload Access Solution
- Join CyberArk's Secure Workload Access Partner Program
- Blog: CyberArk's Vision to Pioneer Secure Access for Workloads
- Blog:Discovery Alone Is Not Enough: You Need Context to Secure Machine Identities
1The CyberArk Secure Workload Access Solution is currently in early availability. An early availability program enables select customers to access technologies before they become generally available.
2Secure Production Identity Framework For Everyone (SPIFFE).
About CyberArk
CyberArk (NASDAQ: CYBR) is the global leader in identity security, trusted by organizations around the world to secure human and machine identities in the modern enterprise. CyberArk's AI-powered Identity Security Platform applies intelligent privilege controls to every identity with continuous threat prevention, detection and response across the identity lifecycle. With CyberArk, organizations can reduce operational and security risks by enabling zero trust and least privilege with complete visibility, empowering all users and identities, including workforce, IT, developers and machines, to securely access any resource, located anywhere, from everywhere. Learn more at cyberark.com.
Copyright © 2025 CyberArk Software. All Rights Reserved. All other brand names, product names, or trademarks belong to their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250410235752/en/
Contacts
Investor Relations:
Srinivas Anantha, CFA
CyberArk
617-558-2132
ir@cyberark.com
Media:
Rachel Gardner
CyberArk
603-531-7229
press@cyberark.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom